Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report)‘s stock had its “equal weight” rating reaffirmed by investment analysts at Wells Fargo & Company in a report issued on Monday, Benzinga reports. They presently have a $1.00 price target on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 138.10% from the company’s previous close.
Several other analysts have also recently commented on SGMO. Barclays reduced their price target on Sangamo Therapeutics from $11.00 to $9.00 and set an “overweight” rating for the company in a report on Wednesday, August 9th. StockNews.com began coverage on shares of Sangamo Therapeutics in a report on Tuesday, October 31st. They issued a “sell” rating for the company. Wedbush reduced their price objective on shares of Sangamo Therapeutics from $16.00 to $10.00 and set an “outperform” rating for the company in a research note on Friday, August 11th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $2.00 target price (down from $6.00) on shares of Sangamo Therapeutics in a report on Friday, November 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of Sangamo Therapeutics in a report on Monday, August 14th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $4.68.
Sangamo Therapeutics Stock Performance
Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). Sangamo Therapeutics had a negative net margin of 123.88% and a negative return on equity of 61.40%. The firm had revenue of $6.84 million during the quarter, compared to analyst estimates of $22.33 million. Equities analysts forecast that Sangamo Therapeutics will post -0.84 earnings per share for the current fiscal year.
In other news, major shareholder Biogen Inc. sold 6,000,000 shares of the firm’s stock in a transaction on Tuesday, September 26th. The shares were sold at an average price of $0.50, for a total value of $3,000,000.00. Following the transaction, the insider now owns 17,652,466 shares of the company’s stock, valued at approximately $8,826,233. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 3.00% of the company’s stock.
Hedge Funds Weigh In On Sangamo Therapeutics
A number of hedge funds have recently made changes to their positions in SGMO. Penserra Capital Management LLC purchased a new stake in Sangamo Therapeutics during the 1st quarter worth $66,000. Lazard Asset Management LLC increased its stake in Sangamo Therapeutics by 37.9% during the 1st quarter. Lazard Asset Management LLC now owns 12,168 shares of the biopharmaceutical company’s stock worth $70,000 after buying an additional 3,342 shares during the period. AlphaCrest Capital Management LLC grew its holdings in Sangamo Therapeutics by 25.4% during the 1st quarter. AlphaCrest Capital Management LLC now owns 14,419 shares of the biopharmaceutical company’s stock worth $84,000 after acquiring an additional 2,919 shares in the last quarter. Hsbc Holdings PLC acquired a new position in Sangamo Therapeutics during the 1st quarter worth $94,000. Finally, Engineers Gate Manager LP acquired a new position in Sangamo Therapeutics during the 3rd quarter worth $80,000. Hedge funds and other institutional investors own 59.81% of the company’s stock.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.
- Five stocks we like better than Sangamo Therapeutics
- Quiet Period Expirations Explained
- GSK is a remedy for the winter investment blahs
- What is the Dow Jones Industrial Average (DJIA)?
- After blowout earnings, Integer may be headed to new highs
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Banking and trucking: Is the economy rolling toward troubles?
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.